SCA
AXSM icon

Snowden Capital Advisors’s Axsome Therapeutics AXSM Stock Holding History

Snowden Capital Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$271K Sell
1,606
-32
-2% -$5.53K 0.01% 1073
2025
Q4 		$299K Buy
+1,638
New +$229K 0.01% 1044

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Snowden Capital Advisors's AXSM Position: Q1 2026 in Review

Snowden Capital Advisors reduced its Axsome Therapeutics (AXSM) stake by 2% in Q1 2026, selling an estimated $5.53K and leaving 1,606 shares worth $271K. The position accounts for 0.01% of the portfolio, ranked #1073.

Snowden Capital Advisors first reported a position in AXSM in Q4 2025 and has held it in 2 quarters since. The position peaked at $299K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Snowden Capital Advisors held 1,606 shares of Axsome Therapeutics worth $271K as of Q1 2026.
  • Snowden Capital Advisors sold 32 Axsome Therapeutics shares in Q1 2026, an estimated $5.53K.
  • Axsome Therapeutics made up 0.01% of Snowden Capital Advisors's portfolio in Q1 2026, its #1073 holding.
  • Snowden Capital Advisors first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Snowden Capital Advisors's Axsome Therapeutics position peaked at $299K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Snowden Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.